Figure 6.
The nomogram containing identified factors for the 1-, 2-, and 3-year OS, LRFS, DDFS and PFS prediction of lung cancer patients. (A) Nomogram for OS, (B) nomogram for LRFS, (C) nomogram for DDFS and (D) nomogram for PFS. D95, the prescription dose covers 95% of the target area; OS, overall survival; LRFS, local recurrence free survival; DDFS, distant disease-free survival; PFS, progression free survival.